Ascletis Pharma (ASCLF) News Today → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free ASCLF Stock Alerts $0.20 0.00 (0.00%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 3, 2024 | prnewswire.comAscletis Announces Strategic Decisions on FXR agonist ASC42March 10, 2024 | prnewswire.comAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual MeetingJanuary 28, 2024 | seekingalpha.comWeek In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From ChinaJanuary 24, 2024 | finance.yahoo.comAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneJanuary 23, 2024 | finance.yahoo.comGannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHJanuary 2, 2024 | finance.yahoo.comGannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic SteatohepatitisDecember 5, 2023 | finance.yahoo.comAscletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneNovember 12, 2023 | finance.yahoo.comAscletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHBNovember 8, 2023 | finance.yahoo.comDr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023November 6, 2023 | finance.yahoo.comGannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&DSeptember 28, 2023 | finance.yahoo.comAscletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional CureSeptember 26, 2023 | msn.comAscletis enrols all patients in trial of glioblastoma therapySeptember 26, 2023 | finance.yahoo.comAscletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent GlioblastomaJuly 24, 2023 | prnewswire.comClinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV ScienceJune 26, 2023 | finance.yahoo.comAscletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023May 8, 2023 | markets.businessinsider.comAscletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV InfectionMay 8, 2023 | finance.yahoo.comAscletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionMay 2, 2023 | finance.yahoo.comAscletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for AcneFebruary 27, 2023 | finance.yahoo.comAscletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech IndexJanuary 31, 2023 | finance.yahoo.comAscletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionJanuary 26, 2023 | finance.yahoo.comAscletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPAJanuary 17, 2023 | msn.comSupply enters ritonavir tablets supply agreement with SimcereJanuary 16, 2023 | finance.yahoo.comAscletis Announces Entering into a Supply Agreement of Ritonavir Tablets with SimcereJanuary 15, 2023 | finance.yahoo.comAscletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19January 3, 2023 | msn.comViking Therapeutics sues Ascletis Pharma for stealing trade secretsDecember 20, 2022 | finance.yahoo.comAscletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as PlannedDecember 19, 2022 | finance.yahoo.comAscletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its DerivativesDecember 12, 2022 | markets.businessinsider.comAscletis Announces Positive Early-Stage Results Of Oral RdRp Inhibitor ASC10 For COVID-19December 12, 2022 | finance.yahoo.comAscletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19December 7, 2022 | marketwatch.comAscletis Pharma Shares Gain After Covid-19 Drug Approved for Clinical TrialDecember 7, 2022 | markets.businessinsider.comAscletis Pharma Announces IND Approval For ASC11 In China - Quick FactsDecember 7, 2022 | seekingalpha.comAscletis gets Chinese drug regulator nod to start trial of oral COVID therapyNovember 30, 2022 | finance.yahoo.comAscletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for AcneNovember 23, 2022 | markets.businessinsider.comAscletis Pharma : FDA Approves IND Of Oral 3CLpro Inhibitor ASC11 For COVID-19November 23, 2022 | finance.yahoo.comAscletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDANovember 16, 2022 | finance.yahoo.comAscletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPANovember 1, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19October 26, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox IndicationOctober 10, 2022 | seekingalpha.comWeek In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong ExchangeOctober 10, 2022 | finance.yahoo.comAscletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19October 4, 2022 | finance.yahoo.comAscletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASHSeptember 29, 2022 | investing.comAscletis Pharma Inc (1672)September 15, 2022 | finance.yahoo.comShanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV InfectionAugust 21, 2022 | nasdaq.comAscletis Pharma : China Approves IND Of Oral RdRp Inhibitor ASC10 For COVID-19August 16, 2022 | finance.yahoo.comGannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary CholangitisAugust 7, 2022 | finance.yahoo.comAscletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid TumorsAugust 3, 2022 | finance.yahoo.comAscletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPAAugust 3, 2022 | finance.yahoo.comAscletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 PatientsJuly 13, 2022 | seekingalpha.comCould Covid Drugs Help Cure Financial Ills At Ascletis Pharma?July 6, 2022 | nasdaq.comAscletis Pharma Announces U.S. IND Filing Of Oral Drug Candidate ASC10 For COVID-19 Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. ASCLF Media Mentions By Week ASCLF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASCLF News Sentiment▼0.000.42▲Average Medical News Sentiment ASCLF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASCLF Articles This Week▼00▲ASCLF Articles Average Week Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Clinuvel Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ASCLF) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Crypto for AIWeiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.